Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

Neurology 2024 Jul 23;103(2):e209584.  doi: 10.1212/WNL.0000000000209584. Epub 2024 Jun 26. Peter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, Genevieve Demarquay, Sait Ashina, Fumihiko Sakai, Brian Neel, Pranav Gandhi , Brett Dabruzzo, Jonathan H Smith, Yingyi Liu, Joel M Trugman Abstract Background and objectives: Atogepant is an oral, calcitonin gene-related peptide receptor antagonist approved

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny